Correlation Between Heart Test and BioSig Technologies,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Heart Test and BioSig Technologies, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Heart Test and BioSig Technologies, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Heart Test Laboratories and BioSig Technologies, Common, you can compare the effects of market volatilities on Heart Test and BioSig Technologies, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Heart Test with a short position of BioSig Technologies,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Heart Test and BioSig Technologies,.

Diversification Opportunities for Heart Test and BioSig Technologies,

-0.58
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Heart and BioSig is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Heart Test Laboratories and BioSig Technologies, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioSig Technologies, and Heart Test is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Heart Test Laboratories are associated (or correlated) with BioSig Technologies,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioSig Technologies, has no effect on the direction of Heart Test i.e., Heart Test and BioSig Technologies, go up and down completely randomly.

Pair Corralation between Heart Test and BioSig Technologies,

Given the investment horizon of 90 days Heart Test Laboratories is expected to under-perform the BioSig Technologies,. But the stock apears to be less risky and, when comparing its historical volatility, Heart Test Laboratories is 2.68 times less risky than BioSig Technologies,. The stock trades about -0.06 of its potential returns per unit of risk. The BioSig Technologies, Common is currently generating about 0.37 of returns per unit of risk over similar time horizon. If you would invest  96.00  in BioSig Technologies, Common on August 29, 2024 and sell it today you would earn a total of  104.00  from holding BioSig Technologies, Common or generate 108.33% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Heart Test Laboratories  vs.  BioSig Technologies, Common

 Performance 
       Timeline  
Heart Test Laboratories 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Heart Test Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Heart Test is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.
BioSig Technologies, 

Risk-Adjusted Performance

18 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in BioSig Technologies, Common are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical and fundamental indicators, BioSig Technologies, displayed solid returns over the last few months and may actually be approaching a breakup point.

Heart Test and BioSig Technologies, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Heart Test and BioSig Technologies,

The main advantage of trading using opposite Heart Test and BioSig Technologies, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Heart Test position performs unexpectedly, BioSig Technologies, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioSig Technologies, will offset losses from the drop in BioSig Technologies,'s long position.
The idea behind Heart Test Laboratories and BioSig Technologies, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements